Oct 4th 2022. Takeda will be discontinuing Natpar globally at the end of 2024. Supply for current patients will be maintained until then and beyond until stock is depleted.
Having worked since 2009 to get PTH 1-84 developed and to market globally we are deeply shocked at this news and our hearts go out to everyone affected. It will now be even more crucial that supplies of One Alpha are maintained in the UK.
Read Takeda’s statement on the discontinuation of NATPAR®/NATPARA® for hypoparathyroidism.